The MLL recombinome of acute leukemias in 2013

Leukemia

Volumn 27, Issue 11, 2013, Pages 2165-2176

  Meyer, C ^a   Hofmann, J ^a   Burmeister, T ^b   Groger D ^b   Park, T S ^c   Emerenciano, M ^d   Pombo De Oliveira, M ^d   Renneville, A ^e   Villarese, P ^f   MacIntyre, E ^f   Cave H ^g   Clappier, E ^g   Mass Malo, K ^g   Zuna, J ^h   Trka, J ^h   De Braekeleer, E ⁱ   De Braekeleer, M ⁱ   Oh, S H ^j   Tsaur, G ^k   Fechina, L ^k   Van Der Velden, V H J ^l   Van Dongen, J J M ^l   Delabesse, E ^m   Binato, R ^d   Silva, M L M ^d   Kustanovich, A ⁿ   Aleinikova, O ⁿ   Harris, M H ^o   Lund Aho, T ^p   Juvonen, V ^q   Heidenreich, O ^r   Vormoor, J ^s   Choi, W W L ^t   Jarosova, M ^u   Kolenova, A ^v   Bueno, C ^w   Menendez, P ^w   Wehner, S ^a   Eckert, C ^b   Talmant, P ^x   Tondeur, S ^y   Lippert, E ^z   Launay, E ^aa   Henry, C ^aa   Ballerini, P ^ab   Lapillone, H ^ab   Callanan, M B ^ac   Cayuela, J M ^g   Herbaux, C ^ad   Cazzaniga, G ^ae   Kakadiya, P M ^af   Bohlander, S ^af   Ahlmann, M ^ag   Choi, J R ^ah   Gameiro, P ^ai   Lee, D S ^aj   Krauter, J ^ak   Cornillet Lefebvre, P ^al   Te Kronnie, G ^am   Schafer B W ^an   Kubetzko, S ^an   Alonso, C N ^ao   Zur Stadt, U ^ap   Sutton, R ^aq   Venn, N C ^aq   Izraeli, S ^ar   Trakhtenbrot, L ^ar   Madsen, H O ^as   Archer, P ^at   Hancock, J ^at   Cerveira, N ^au   Teixeira, M R ^au   Lo Nigro, L ^av   Moricke A ^aw   Stanulla, M ^aw   Schrappe, M ^aw   Sedek L ^ax   Szczepanski T ^ax   Zwaan, C M ^ay   Coenen, E A ^ay   Van Den Heuvel Eibrink, M M ^ay   Strehl, S ^az   Dworzak, M ^az   Panzer Grumayer R ^az   Dingermann, T ^a   Klingebiel, T ^a   Marschalek, R ^a   more..

^a GOETHE UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Kyung Hee University Hospital   (South Korea)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^j Inje University College of Medicine   (South Korea)

^k Research Institute of Medical Cell Technologies   (Russian Federation)

^l ERASMUS MEDICAL CENTER   (Netherlands)

^m CHU PURPAN   (France)

ⁿ Belarusian Research Center for Pediatric Oncology Hematology and Immunology   (Belarus)

^o BOSTON CHILDREN S HOSPITAL   (United States)

^p FIMLAB LABORATORIES   (Finland)

^q TURKU UNIVERSITY HOSPITAL   (Finland)

^r NEWCASTLE UNIVERSITY   (United Kingdom)

^s NEWCASTLE UNIVERSITY   (United Kingdom)

^t UNIVERSITY OF HONG KONG   (Hong Kong)

^u PALACKÝ UNIVERSITY   (Czech Republic)

^v Bratislava   (Slovakia)

^w UNIVERSITY OF GRANADA   (Spain)

^x NANTES UNIVERSITY HOSPITAL   (France)

^y MONTPELLIER UNIVERSITY HOSPITAL   (France)

^z BORDEAUX UNIVERSITY HOSPITAL   (France)

^aa RENNES UNIVERSITY HOSPITAL   (France)

^ab SORBONNE UNIVERSITÉ   (France)

^ac INSTITUT ALBERT BONNIOT   (France)

^ad CENTRE HOSPITALIER DE VALENCIENNES   (France)

^ae UNIVERSITY OF MILANO BICOCCA   (Italy)

^af PHILIPPS UNIVERSITY MARBURG   (Germany)

^ag UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^ah Yonsei University College of Medicine   (South Korea)

^ai INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^aj Seoul National University College of Medicine   (South Korea)

^ak HANNOVER MEDICAL SCHOOL   (Germany)

^al Lab d'Hematologie Hemostase   (France)

^am UNIVERSITY OF PADOVA   (Italy)

^an UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^ao Hospital Nacional de Pediatrý a   (Argentina)

^ap UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^aq UNIVERSITY OF NEW SOUTH WALES   (Australia)

^ar SHEBA MEDICAL CENTER   (Israel)

^as Rigshospitalet   (Denmark)

^at SOUTHMEAD HOSPITAL   (United Kingdom)

^au UNIVERSITY OF PORTO   (Portugal)

^av UNIVERSITY OF CATANIA   (Italy)

^aw UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^ax MEDICAL UNIVERSITY OF SILESIA   (Poland)

^ay SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^az MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

acute leukemia; ALL; AML; chromosomal translocations; MLL; translocation partner genes

Indexed keywords

MIXED LINEAGE LEUKEMIA PROTEIN; RNA POLYMERASE II;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CELL ADHESION; CELL DIVISION; CELL MIGRATION; CHILD; CHROMATIN; CHROMOSOME 11; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOGENETICS; DIMERIZATION; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DNA STRAND BREAKAGE; DOUBLE STRANDED DNA BREAK; EXON; FEMALE; FUSION GENE; GENE LOCATION; GENE LOCUS; GENETIC RECOMBINATION; HUMAN; INFANT; INTRON; ISOMERIZATION; MALE; NEWBORN; OLIGOMERIZATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD; START CODON;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANIMALS; CHILD; CHILD, PRESCHOOL; CHROMOSOME BREAKAGE; FEMALE; GENE REARRANGEMENT; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA; MALE; MICE; MIDDLE AGED; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PROGNOSIS; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84887320453     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.135     Document Type: Article

References (60)

1. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909-1915. (Pubitemid 34615770)
2. Pui CH, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 2003; 17: 700-706. (Pubitemid 36519366)
3. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an International Retrospective Sstudy. Blood 2009; 114: 2489-2496.
4. Szczepań ski T, Harrison CJ, van Dongen JJ. Genetic aberrations in paediatric acute leukaemias and implications for management of patients. Lancet Oncol 2010; 11: 880-889.
5. Burmeister T, Marschalek R, Schneider B, Meyer C, Gökbuget N, Schwartz S et al. Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia 2006; 20: 451-457. (Pubitemid 43291743)
6. van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009; 23: 1073-1079.
7. Yeoh AE, Ariffin H, Chai EL, Kwok CS, Chan YH, Ponnudurai K et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol 2012; 30: 2384-2392.
8. Johansson B, Moorman AV, Secker-Walker LM. Derivative chromosomes of 11q23-translocations in hematologic malignancies. European 11q23 Workshop participants. Leukemia 1998; 12: 828-833. (Pubitemid 28220843)
9. Heerema NA, Sather HN, Ge J, Arthur DC, Hilden JM, Trigg ME et al. Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11)-a report of the Children's Cancer Group. Leukemia 1999; 13: 679-686. (Pubitemid 29243617)
10. Van der Burg M, Beverloo HB, Langerak AW, Wijsman J, van Drunen E, Slater R et al. Rapid and sensitive detection of all types of MLL gene translocations with a single FISH probe set. Leukemia 1999; 13: 2107-2113.
11. van der Burg M, Poulsen TS, Hunger SP, Beverloo HB, Smit EM, Vang-Nielsen K et al. Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia. Leukemia 2004; 18: 895-908. (Pubitemid 38714612)
12. Harrison CJ, Moorman AV, Barber KE, Broadfield ZJ, Cheung KL, Harris RL et al. Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. Br J Haematol 2005; 129: 520-530. (Pubitemid 40769901)
13. Meyer C, Schneider B, Reichel M, Angermueller S, Strehl S, Schnittger S et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci USA 2005; 102: 449-454. (Pubitemid 40116787)
14. Meyer C, Schneider B, Jakob S, Strehl S, Schnittger S, Schoch C et al. The MLL recombinome of acute leukemias. Leukemia 2006; 20: 777-784.
15. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J et al. New insights into the MLL recombinome of acute leukemias. Leukemia 2009; 23: 1490-1499.
16. Daser A, Rabbitts TH. The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis. Semin Cancer Biol 2005; 15: 175-188.
17. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7: 823-833. (Pubitemid 350006257)
18. Emerenciano M, Meyer C, Mansur MB, Marschalek R, Pombo-de-Oliveira MS. The Brazilian Collaborative Study Group of Infant Acute Leukaemia. The distribution of MLL breakpoints correlates with outcome in infant acute leukaemia. Br J Haematol 2013; 161: 224-236.
19. Linder B, Newman R, Jones LK, Debernardi S, Young BD, Freemont P et al. Biochemical analyses of the AF10 protein: the extended LAP/PHD-finger mediates oligomerisation. J Mol Biol 2000; 299: 369-378.
20. Fair K, Anderson M, Bulanova E, Mi H, Tropschug M, Diaz MO. Protein interactions of the MLL PHD fingers modulate MLL target gene regulation in human cells. Mol Cell Biol 2001; 21: 3589-3597. (Pubitemid 32381794)
21. Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci USA 2003; 100: 8342-8347. (Pubitemid 36842547)
22. Chang PY, Hom RA, Musselman CA, Zhu L, Kuo A, Gozani O et al. Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription. J Mol Biol 2010; 400: 137-144.
23. Wang Z, Song J, Milne TA, Wang GG, Li H, Allis CD et al. Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression. Cell 2010; 141: 1183-1194.
24. Wang J, Muntean AG, Hess JL. ECSASB2 mediates MLL degradation during hematopoietic differentiation. Blood 2012; 119: 1151-1161.
25. Wang J, Muntean AG, Wu L, Hess JL. A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity. J Biol Chem 2012; 287: 43410-43416.
26. Grow EJ, Wysocka J. Flipping MLL1's switch one proline at a time. Cell 2010; 141: 1108-1010.
27. Strissel PL, Strick R, Rowley JD, Zeleznik-Le NJ. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood 1998; 92: 3793-3803. (Pubitemid 28525206)
28. Stanulla M, Wang J, Chervinsk DS, Thandla S, Aplan PD. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higherorder chromatin fragmentation during the initial stages of apoptosis. Mol Cell Biol 1997; 17: 4070-4079. (Pubitemid 27281883)
29. Scharf S, Zech J, Bursen A, Schraets D, Oliver PL, Kliem S et al. Transcription linked to recombination: a gene-internal promoter coincides with the recombination hot spot II of the human MLL gene. Oncogene 2007; 26: 1361-1371. (Pubitemid 46340820)
30. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 2001; 36: 525-535. (Pubitemid 32336557)
31. Wang S, Zhang Z, Ying K, Chen JZ, Meng XF, Yang QS et al. Cloning, expression, and genomic structure of a novel human Rap2 interacting gene (RPIP9). Biochem Genet 2003; 41: 13-25. (Pubitemid 36206822)
32. Raychaudhuri S, Sinha M, Mukhopadhyay D, Bhattacharyya NP. HYPK, a Huntingtin interacting protein, reduces aggregates and apoptosis induced by N-terminal Huntingtin with 40 glutamines in Neuro2a cells and exhibits chaperone-like activity. Hum Mol Genet 2008; 17: 240-255.
33. Grote M, Wolf E, Will CL, Lemm I, Agafonov DE, Schomburg A et al. Molecular architecture of the human Prp19/CDC5L complex. Mol Cell Biol 2010; 30: 2105-2119.
34. Vander Kooi CW, Ohi MD, Rosenberg JA, Oldham ML, Newcomer ME, Gould KL et al. The Prp19 U-box crystal structure suggests a common dimeric architecture for a class of oligomeric E3 ubiquitin ligases. Biochemistry 2006; 45: 121-130. (Pubitemid 43054089)
35. Sihn CR, Cho SY, Lee JH, Lee TR, Kim SH. Mouse homologue of yeast Prp19 interacts with mouse SUG1, the regulatory subunit of 26S proteasome. Biochem Biophys Res Commun 2007; 356: 175-180. (Pubitemid 46413146)
36. Lö scher M, Fortschegger K, Ritter G, Wostry M, Voglauer R, Schmid JA et al. Interaction of U-box E3 ligase SNEV with PSMB4, the beta7 subunit of the 20S proteasome. Biochem J 2005; 388: 593-603. (Pubitemid 40839937)
37. Pan YR, Lee EY. UV-dependent interaction between Cep164 and XPA mediates localization of Cep164 at sites of DNA damage and UV sensitivity. Cell Cycle 2009; 8: 655-664.
38. Sivasubramaniam S, Sun X, Pan YR, Wang S, Lee EY. Cep164 is a mediator protein required for the maintenance of genomic stability through modulation of MDC1, RPA, and CHK1. Genes Dev 2008; 22: 587-600. (Pubitemid 351342432)
39. Baisamy L, Cavin S, Jurisch N, Diviani D. The ubiquitin-like protein LC3 regulates the Rho-GEF activity of AKAP-Lbc. J Biol Chem 2009; 284: 28232-28242.
40. Shibolet O, Giallourakis C, Rosenberg I, Mueller T, Xavier RJ, Podolsky DK. AKAP13, a RhoA GTPase-specific guanine exchange factor, is a novel regulator of TLR2 signaling. J Biol Chem 2007; 282: 35308-35317. (Pubitemid 350232485)
41. Smith FD, Langeberg LK, Cellurale C, Pawson T, Morrison DK, Davis RJ et al. AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. Nat Cell Biol 2010; 12: 1242-1249.
42. Liu P, Tarlé SA, Hajra A, Claxton DF, Marlton P, Freedman M et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261: 1041-1044. (Pubitemid 23300863)
43. Reichel M, Gillert E, Nilson I, Siegler G, Greil J, Fey GH et al. Fine structure of translocation breakpoints in leukemic blasts with chromosomal translocation t(4;11): the DNA damage-repair model of translocation. Oncogene 1998; 17: 3035-3044. (Pubitemid 29012207)
44. Richardson C, Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature 2000; 405: 697-700. (Pubitemid 30428657)
45. Schichman SA, Caligiuri MA, Gu Y, Strout MP, Canaani E, Bloomfield CD et al. ALL-1 partial duplication in acute leukemia. Proc Natl Acad Sci USA 1994; 91: 6236-6239. (Pubitemid 24188318)
46. Martin ME, Milne TA, Bloyer S, Galoian K, Shen W, Gibbs D et al. Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell 2003; 4: 197-207. (Pubitemid 37163834)
47. Bäsecke J, Whelan JT, Griesinger F, Bertrand FE. The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol 2006; 135: 438-449. (Pubitemid 44583410)
48. Meyer C, Burmeister T, Strehl S, Schneider B, Hubert D, Zach O et al. Spliced MLL fusions: a novel mechanism to generate functional chimeric MLL-MLLT1 transcripts in t(11;19)(q23;p13.3) leukemia. Leukemia 2007; 21: 588-590.
49. Holland AJ, Cleveland DW. Chromoanagenesis and cancer: mechanisms and consequences of localized, complex chromosomal rearrangements. Nat Med 2012; 18: 1630-1638.
50. Bursen A, Schwabe K, Rü ster B, Henschler R, Ruthardt M, Dingermann T et al. AF4-MLL is capable of inducing ALL in mice without requirement of MLL-AF4. Blood 2010; 115: 3570-3579.
51. Emerenciano M, Kowarz E, Karl K, de Almeida Lopes B, Scholz B, Bracharz S et al. Functional analysis of the two reciprocal fusion genes MLL-NEBL and NEBL-MLL reveal their oncogenic potential. Cancer Lett 2013; 332: 30-34.
52. Zeisig DT, Bittner CB, Zeisig BB, Garc?́a-Cué llar MP, Hess JL, Slany RK. The elevennineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene 2005; 24: 5525-5532. (Pubitemid 43080096)
53. Bitoun E, Oliver PL, Davies KE. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 2007; 16: 192-106.
54. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005; 121: 167-178. (Pubitemid 40546386)
55. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001; 15: 2343-2360. (Pubitemid 32899739)
56. Benedikt A, Baltruschat S, Scholz B, Bursen A, Arrey TN, Meyer B et al. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia 2011; 25: 135-144.
57. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008; 14: 355-368.
58. Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J et al. RUNX1 Is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep 2013; 3: 116-127.
59. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20: 53-65.
60. Bursen A, Moritz S, Gaussmann A, Dingermann T, Marschalek R. Interaction of AF4 wildtype and AF4-MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology? Oncogene 2004; 23: 6237-6249.